HCW Total Current Liabilities vs Asset Turnover Analysis
| HCWB Stock | USD 0.77 0.06 8.45% |
HCW Biologics financial indicator trend analysis is much more than just examining HCW Biologics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether HCW Biologics is a good investment. Please check the relationship between HCW Biologics Total Current Liabilities and its Asset Turnover accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
Total Current Liabilities vs Asset Turnover
Total Current Liabilities vs Asset Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of HCW Biologics Total Current Liabilities account and Asset Turnover. At this time, the significance of the direction appears to have pay attention.
The correlation between HCW Biologics' Total Current Liabilities and Asset Turnover is -0.74. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of HCW Biologics, assuming nothing else is changed. The correlation between historical values of HCW Biologics' Total Current Liabilities and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of HCW Biologics are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Total Current Liabilities i.e., HCW Biologics' Total Current Liabilities and Asset Turnover go up and down completely randomly.
Correlation Coefficient | -0.74 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Total Current Liabilities
Total Current Liabilities is an item on HCW Biologics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of HCW Biologics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most indicators from HCW Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into HCW Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.At present, HCW Biologics' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 62.6 M, whereas Selling General Administrative is forecasted to decline to about 6.8 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 543.6K | 1.1M | 717.9K | Interest Income | 505.4K | 581.2K | 610.2K |
HCW Biologics fundamental ratios Correlations
Click cells to compare fundamentals
HCW Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.